Allweiss L, Dandri M (2017) The role of cccDNA in HBV maintenance. Viruses 9:156. https://doi.org/10.3390/v9060156
Article CAS PubMed PubMed Central Google Scholar
Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218. https://doi.org/10.1172/JCI24282
Bonacci M, Lens S, Mariño Z et al (2018) Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone. Aliment Pharmacol Ther 47:1397–1408. https://doi.org/10.1111/apt.14613
Article CAS PubMed Google Scholar
Butler EK, Gersch J, McNamara A et al (2018) Hepatitis B virus serum DNA and RNA levels in Nucleos(t)ide analog-treated or untreated patients during chronic and acute infection. Hepatology 68:2106–2117. https://doi.org/10.1002/hep.30082
Article CAS PubMed Google Scholar
Carey I, Gersch J, Wang B et al (2020) Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(T)ide analogue therapy. Hepatology 72:42–57. https://doi.org/10.1002/hep.31026
Article CAS PubMed Google Scholar
Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association (2019) The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Chin J Hepatol 35:2468–2669. https://doi.org/10.3760/cma.j.issn.1007-3418.2015.12.002
Coffin CS, Zhou K, Terrault NA (2019) New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection. Gastroenterology 156:355-368.e3. https://doi.org/10.1053/j.gastro.2018.11.037
Article CAS PubMed Google Scholar
Fanning GC, Zoulim F, Hou J, Bertoletti A (2019) Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov 18:827–844. https://doi.org/10.1038/s41573-019-0037-0
Article CAS PubMed Google Scholar
Ghany MG, King WC, Lisker-Melman M et al (2021) Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America. Hepatology 74:2395–2409. https://doi.org/10.1002/hep.32018
Article CAS PubMed Google Scholar
Giersch K, Allweiss L, Volz T et al (2017) Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol 66:460–462. https://doi.org/10.1016/j.jhep.2016.09.028
Article CAS PubMed Google Scholar
Henderson NC, Rieder F, Wynn TA (2020) Fibrosis: from mechanisms to medicines. Nature 587:555–566. https://doi.org/10.1038/s41586-020-2938-9
Höner zu Siederdissen C, Maasoumy B, Cornberg M (2017) What is new on HBsAg and other diagnostic markers in HBV infection. Best Pract Res Clin Gastroenterol 31:281–289. https://doi.org/10.1016/j.bpg.2017.04.009
Article CAS PubMed Google Scholar
Huang H, Wang J, Li W et al (2018) Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. J Clin Virol 99–100:71–78. https://doi.org/10.1016/j.jcv.2017.12.016
Article CAS PubMed Google Scholar
Huang C, Li Q, Xu W et al (2020) Serum HBV RNA levels predict significant liver fibrosis in patients with chronic HBV infection. Discov Med 29:119–128
Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC (2008) Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47:1363–1370. https://doi.org/10.1002/hep.22109
Article CAS PubMed Google Scholar
Köck J, Theilmann L, Galle P, Schlicht H (1996) Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus: hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology 23:405–413. https://doi.org/10.1002/hep.510230303
Lai C-L, Wong D, Ip P et al (2017) Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol 66:275–281. https://doi.org/10.1016/j.jhep.2016.08.022
Article CAS PubMed Google Scholar
Liao H, Li L, Zheng WV et al (2022) Characteristics of HBV novel serum markers across distinct phases in treatment-naïve chronic HBV-infected patients. Dis Markers 2022:1–13. https://doi.org/10.1155/2022/4133283
Liu S, Zhou B, Valdes JD et al (2019) Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection. Hepatology 69:1816–1827. https://doi.org/10.1002/hep.30325
Liu S, Liu Z, Li W et al (2020) Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues. Aliment Pharmacol Ther 52:692–700. https://doi.org/10.1111/apt.15890
Article CAS PubMed Google Scholar
Lok ASF, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45:507–539. https://doi.org/10.1002/hep.21513
Article CAS PubMed Google Scholar
Mak L, Cloherty G, Wong DK et al (2021) HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy. Hepatology 73:2167–2179. https://doi.org/10.1002/hep.31616
Article CAS PubMed Google Scholar
Nassal M (2015) HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64:1972–1984. https://doi.org/10.1136/gutjnl-2015-309809
Article CAS PubMed Google Scholar
Nguyen MH, Wong G, Gane E et al (2020) Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev 33:e00046-e119. https://doi.org/10.1128/CMR.00046-19
Article PubMed PubMed Central Google Scholar
Ren S, Wang W, Lu J et al (2022) Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone. Front Immunol 13:1035923. https://doi.org/10.3389/fimmu.2022.1035923
Article CAS PubMed PubMed Central Google Scholar
Rockey DC, Caldwell SH, Goodman ZD et al (2009) Liver biopsy. Hepatology 49:1017–1044. https://doi.org/10.1002/hep.22742
Russo FP, Imondi A, Lynch EN, Farinati F (2018) When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Dig Liver Dis 50:640–646. https://doi.org/10.1016/j.dld.2018.03.014
Schcuer J (1991) Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13:372–374. https://doi.org/10.1016/0168-8278(91)90084-o
Shen S, Xie Z, Cai D et al (2020) Biogenesis and molecular characteristics of serum hepatitis B virus RNA. PLoS Pathog 16:e1008945. https://doi.org/10.1371/journal.ppat.1008945
Article CAS PubMed PubMed Central Google Scholar
Tang LSY, Covert E, Wilson E, Kottilil S (2018) Chronic hepatitis B infection: a review. JAMA 319:1802. https://doi.org/10.1001/jama.2018.3795
Article CAS PubMed Google Scholar
Terrault NA, Bzowej NH, Chang K-M et al (2016) AASLD guidelines for treatment of chronic hepatitis B: hepatology, month 2015. Hepatology 63:261–283. https://doi.org/10.1002/hep.28156
Terrault N, Lok A, McMahon B et al (2018) Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67:1560–1599. https://doi.org/10.1002/hep.29800
Tsuge M, Murakami E, Imamura M et al (2013) Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol 48:1188–1204. https://doi.org/10.1007/s00535-012-0737-2
Article CAS PubMed Google Scholar
van Bömmel F, van Bömmel A, Krauel A et al (2018) Serum HBV RNA as a predictor of peginterferon Alfa-2a response in patients with HBeAg-positive chronic hepatitis B. J Infect Dis 218:1066–1074. https://doi.org/10.1093/infdis/jiy270
Wang J, Yu Y, Li G et al (2018a) Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat 25:1038–1047. https://doi.org/10.1111/jvh.12908
Article CAS PubMed Google Scholar
Wang J, Yu Y, Li G et al (2018b) Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol 68:16–24. https://doi.org/10.1016/j.jhep.2017.08.021
Wang X, Chi X, Wu R et al (2021) Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment. Virol J 18:4. https://doi.org/10.1186/s12985-020-01471-2
Comments (0)